Genzyme Sues Impax Labs Over ANDA For Renvela
The Cambridge, Mass.-based drugmaker filed suit Friday in the U.S. District Court for the District of Maryland over U.S. Patent Number 5,667,775, which covers both Renvela and Renagel, its predecessor drug.
Genzyme filed the suit after learning Feb. 23 that Impax had submitted an abbreviated new drug application to the U.S. Food...
Already a subscriber? Click here to login